Dr. Stuart Essig currently serves as Managing Director of Prettybrook Partners LLC, his family office investing in medical technology companies. He is also Chair of the Board of Directors of Integra LifeSciences Holdings Corporation (NASDAQ:IART), a position he has held since 2012 and Chair of the Board of Directors for Mission BIo Inc.
Dr. Essig served as Integra’s CEO from December 1997 until January 2012, building Integra into a global surgical products leader. During his 26-year tenure with the company, Integra has grown revenues from $15 million to almost $1.6 billion and its market capitalisation from approximately $100 million to a levered valuation of more than $5 billion. Before joining Integra, Dr. Essig was Managing Director of the medical technology practice at Goldman, Sachs & Co. He had ten years of broad healthcare experience at Goldman Sachs, serving as a senior merger and acquisitions advisor to a broad range of domestic and international medical technology, pharmaceutical and biotechnology clients. Dr. Essig has chaired audit, compensation, finance and nominating and governance committees, served as lead director, and participated in CEO succession processes, on the boards of numerous public companies, ranging in size from several hundred million dollars to over $40 billion in levered market capitalisation. In addition to Integra, Dr. Essig currently serves on the Board of Directors of IDEXX Laboratories (NASDAQ: IDXX) and Orthofix Corporation (NASDAQ:OFIX). He is also the Lead Director, and former Executive Chair, of the Board of Directors of private-equity backed Breg, Inc., a premium provider of high-value sports medicine products, and also serves as Audit Committee Chair of Availity, LLC, the nation’s largest real-time health information network. He previously served as an executive-in-residence at Cardinal Partners and currently serves as a venture partner at Wellington Partners Advisory AG, both venture capital firms. He also served as a senior advisor to Water Street Healthcare Partners. Dr. Essig was a founding investor member of Tigerlabs, a Princeton-based business accelerator. He serves on the Leadership Counsel of the Princeton University School of Engineering and Applied Sciences, and served on the NACD Compensation Committee Chair Advisory Council. Dr. Essig previously served on the Board of Directors of Owens & Minor, Inc. (NYSE:OMI) from 2013 to 2019, Seaspine Corporation (NASDAQ:SPNE) from 2015 to 2023, and St. Jude Medical Corporation (NYSE:SJM) from 1999 to 2017, prior to its sale to Abbott Corporation. From 2005 until 2008 he served on the Board of Directors of Zimmer Holdings, Inc. (NYSE:ZMH), and from 1998 to 2002, he served on the Board of Directors of Vital Signs, Inc. (NASDAQ:VITL). He also served on the executive committee, nominating and governance committee, and as treasurer of ADVAMED, the Advanced Medical Technology Association. Dr. Essig is also involved in several non-profit charitable organizations, including from time to time serving on their boards.
